MONOVISC® High Molecular Weight Hyaluronan is an FDA approved treatment made from ultra-pure hyaluronan, a naturally occurring lubricant found in healthy knee joints. MONOVISC® is a non-avian sourced viscosupplement that provides early and durable pain relief in a single high concentration injection that is conveniently packaged in a 4 mL volume for ease of use by physicians and minimum injection discomfort for patients.



For proven fast and long-lasting pain relief


Ensures long-lasting retention time of the hyaluronic acid


FDA approval by placebo-controlled, randomized, double-blind, multicenter study


Only one injection in the therapy cycle and 10 years of Monovisc therapy experience



  • MONOVISC® delivers a high active ingredient content compared to other cross-linked one-shot preparations available on the market. One 4 ml injection contains 88 mg of hyaluronic acid at a concentration of 22 mg/ml.

  • Injecting high-dose MONOVISC® reduces pain better than other preparations and prolongs the pain-free phase.

  • MONOVISC® is manufactured in a patented crossliniking process and has a slightly crosslinked molecular structure. The resulting stabilized hyaluronic acid remains longer in the joint.

HyaloFast® has been used in the field of tissue regeneration for more than 15 years
and has an excellent safety profile. 
When HYAFF is degraded to HS, 
it is naturally absorbed in the body.


Spherox has been shown to improve patients’ symptoms and knee function in two studies in adults between 18 and 50 years of age. The main measure of effectiveness was the KOOS (knee injury and osteoarthritis outcome score), which is graded on a scale from 0 to 100 (where 0 means severest symptoms and 100 means no symptoms). The KOOS was self-measured by patients, who rated the severity of their symptoms such as pain, impact on daily living, sport and recreational activities, and quality of life.

In the first study involving 100 adults, Spherox was compared with microfracture (a type of surgery used to treat defects in cartilage). The knee cartilage defects were between 1 and 4 cm2 in size. Data from this study showed that Spherox improved the outcome score by 22 points to 28 points until 5 years after treatment and was as effective as microfracture.

The second study looked at 73 adults with large cartilage defects of the knee from 4 to 10 cm². All these patients received treatment with Spherox, as microfracture is not recommended to repair such large defects. In this study, patients’ outcome scores with Spherox improved by 16 points in the first year and further improvements were seen up to three years after treatment and remained stable until five years after treatment.

A third study looked at the treatment effect with Spherox in 105 adolescents aged between 15 and 17 years with cartilage defects of the knee joint. Overall, the results indicated that there was no major difference in terms of effectiveness between the adolescents included in this study and the young adults (from 18 to 34 years of age) who participated in the previous two studies.

Orthopedics & Traumatology Monovisc 4 ml